Hydrogen Sulfide, Serotonin Control, and Why Gut Motility Becomes Unstable

When most people hear that serotonin affects the gut, they assume the issue is simple. They think the question is whether the body is making too much serotonin or not enough. That sounds reasonable on the surface, but it leaves out the most important part of the system. Gut function does not depend only on how much serotonin is present. It depends on how precisely serotonin is released, how long it stays active, how quickly it is cleared, how well the receptors respond to it, and whether the cells involved in movement have enough energy to do their job. Once you understand that, you begin to see why gut motility problems are often much more complex than they first appear.

Serotonin is one of the major signaling molecules in the gastrointestinal tract. Most of the body’s serotonin is produced in the gut, mainly by specialized cells called enterochromaffin cells. These cells sense what is happening inside the intestinal environment and release serotonin in response to food, mechanical stretch, chemicals, and microbial signals. Once serotonin is released, it communicates with the enteric nervous system, which is the dense network of neurons embedded in the gut wall. This system helps regulate contractions, secretion, sensation, and communication between the gut and the brain.

But serotonin is not supposed to remain active for a long time. It is designed to act as a controlled signal, not as continuous noise. After serotonin has activated its receptors, it needs to be cleared. That job is handled by the serotonin transporter, called SERT, which is encoded by the SLC6A4 gene. SERT pulls serotonin back into cells and ends the signal. This is a critical step because the gut does not only need serotonin. It needs serotonin to appear at the right time and disappear at the right time.

That timing issue is where many models of gut dysfunction become too simplistic. If serotonin is cleared too quickly, the signal becomes too weak and too short to properly coordinate movement. If serotonin is not cleared efficiently, it remains outside the cells for too long and overstimulates receptors. In both cases the system becomes disorganized. So the real question is often not whether serotonin is high or low. The real question is whether the gut still has proper control over serotonin signaling.

To understand why this matters, it helps to understand the migrating motor complex, often called the MMC. The MMC is a cyclical pattern of electrical and muscular activity that occurs mainly during fasting, between meals. It is one of the gut’s most important housekeeping systems. During this fasting state, the stomach and small intestine do not simply remain inactive. Instead, they go through recurring waves of organized activity. There is a quieter phase, then a phase of irregular contractions, and then a stronger phase of coordinated contractions that travel through the small intestine. This stronger phase acts like a cleaning wave. It helps sweep residual food particles, mucus, cellular debris, and bacteria through the small intestine and down toward the colon.

This matters because the small intestine is not meant to function like the colon. It normally has a lower bacterial burden and a different ecological environment. The MMC helps protect that structure. When the MMC weakens or becomes disorganized, bacteria can remain in the small intestine longer than they should. This can promote fermentation in the wrong location, contribute to bloating and gas, alter nutrient handling, and encourage a microbial pattern that keeps the system irritated. So when people talk about motility, they are not just talking about whether someone feels constipated or whether stool moves. They are talking about whether the gut’s housekeeping system is still working correctly.

Serotonin plays an important role in this process. One of the key receptor subtypes involved in pro-motility signaling is the 5-HT4 receptor. Activation of 5-HT4 receptors helps stimulate enteric neurons to release acetylcholine and other signals that support coordinated propulsion. In simpler terms, serotonin helps tell the gut nervous system when to initiate organized movement. Another receptor, 5-HT3, is more strongly linked to sensory signaling. When 5-HT3 pathways are overactivated, people may experience nausea, urgency, cramping, and heightened visceral sensitivity. This is one reason serotonin can be associated with both movement and discomfort. Different receptors are doing different jobs.

Now we can introduce hydrogen sulfide, which adds another layer to the picture. Hydrogen sulfide is a gas produced in the gut by both host pathways and certain microbes, especially sulfur-metabolizing organisms. At low physiological levels, hydrogen sulfide is not automatically harmful. Like nitric oxide and carbon monoxide, it can serve signaling functions in the body. The problem begins when hydrogen sulfide is produced in excess, persists chronically, or appears in the wrong context. Then it shifts from being a regulated signaling molecule to a disruptor of protein function and mitochondrial function.

One of the important chemical actions of hydrogen sulfide is that it can modify cysteine residues in proteins through a process known as persulfidation. Proteins are not static structures. Their shape matters, their folding matters, and their placement in the cell membrane matters. If hydrogen sulfide modifies key cysteine residues on a protein, the protein may change how it behaves. This is important for SERT because SERT is not just a passive pump. It is a membrane protein that depends on correct folding, stability, and localization in order to clear serotonin properly. If hydrogen sulfide alters its structure or membrane behavior, serotonin clearance can become abnormal.

This is where the model becomes especially interesting. If hydrogen sulfide changes SERT function, the gut may lose control over serotonin timing. In one scenario, serotonin may be cleared too quickly. If that happens, the pro-motility signal becomes too brief, and receptors like 5-HT4 do not receive the sustained stimulation needed for good coordination. In another scenario, serotonin may not be cleared well enough, so it builds up outside the cells and overstimulates receptors such as 5-HT3. That can initially produce urgency, discomfort, and a sense of overactivity. Both scenarios are forms of dysregulation. One creates a weak, cut-short signal. The other creates an excessive, poorly terminated signal.

Many people stop the story there, but the most important part is what happens over time. Biological systems adapt. If serotonin receptors are overstimulated chronically, they do not just keep responding at the same intensity. They begin to desensitize. This means the receptor becomes less responsive to the same signal. Mechanistically, receptors can be phosphorylated, regulatory proteins can bind to them, and they can be internalized or functionally dampened. In practical terms, the receptor becomes harder to activate.

This adaptation helps explain why gut symptoms often change over time instead of remaining stable. A person may begin with urgency, diarrhea, heightened sensitivity, or a sense that the gut is overreactive. But if receptor overstimulation continues, the system can shift into a less responsive state. The same gut that once felt overactive may later feel sluggish, poorly coordinated, and resistant to stimulation. This is one reason some people describe a history of symptoms that changed from one extreme to another. That pattern is not necessarily random. It may reflect progression from overstimulation to receptor desensitization.

This also helps explain why serotonin-based treatments do not always work as expected. Current pro-motility treatments often try to stimulate parts of this system. Drugs such as prucalopride and tegaserod act on 5-HT4 receptors to support motility. Other agents, such as erythromycin, work through motilin pathways and are sometimes used to stimulate upper gut motility. Metoclopramide works through dopamine antagonism and has prokinetic effects as well. Each of these interventions can be useful in certain contexts, but they all implicitly assume that the underlying machinery is still capable of responding in an organized way.

That assumption is often too generous. If serotonin receptors have already become desensitized, stimulating them more may produce a weaker-than-expected result. If SERT is still dysfunctional, serotonin timing remains abnormal even while a medication is trying to push the system. If the gut cells lack energy, then even a correct signal may not translate into effective movement. In other words, giving a prokinetic is not the same as restoring the health of the signaling system. A drug may push on one lever while the rest of the machine remains impaired.

The energy side of the problem is crucial and often underappreciated. Gut motility is not just a neurotransmitter issue. It is also a bioenergetic issue. The intestinal nervous system requires ATP. Smooth muscle contraction requires ATP. Ion gradients require ATP. Coordinated movement requires energy at every level. Hydrogen sulfide is especially important here because at higher levels it can inhibit cytochrome c oxidase, which is Complex IV of the mitochondrial electron transport chain. That means the cell’s ability to use oxygen to generate ATP can be impaired. Once that happens, the system has a signal problem and an execution problem at the same time. The gut may receive impaired signals, and even when the signal is present, the tissue may not have enough energy to act on it properly.

This is one of the deepest flaws in the simplistic serotonin model. It treats motility as if it were only a matter of neurotransmitter availability. But the gut is not an abstract signaling diagram. It is living tissue that needs energy to perform work. If hydrogen sulfide is modifying transporters and also reducing mitochondrial performance, then the disorder cannot be reduced to serotonin alone. It becomes a systems problem involving signaling kinetics, receptor responsiveness, mitochondrial capacity, microbial ecology, and tissue execution.

The antidepressant layer adds yet another complication. Selective serotonin reuptake inhibitors, or SSRIs, such as fluoxetine, sertraline, citalopram, escitalopram, and paroxetine, act by inhibiting SERT. In the brain, this is used to increase serotonin availability in synapses. But SERT is not only in the brain. It is also in the gut. So when SSRIs inhibit SERT in the gut, serotonin signaling there can also change. In the short term this may increase serotonin availability and alter motility, sensation, or bowel habits. Some people notice diarrhea, nausea, increased motility, or sensory changes after starting these medications. Over time, however, chronic receptor exposure can contribute to adaptive changes, including desensitization. This is one reason responses can become complex and variable. A person may not simply experience a stable increase in serotonin activity. They may experience a shifting system that changes as receptors, transporters, neurons, and gut tissues adapt.

That does not mean SSRIs are universally harmful or that they should be reduced to a one-dimensional explanation. But it does mean that in a person whose serotonin signaling is already dysregulated, whose SERT function may already be compromised, or whose gut ecology is already promoting hydrogen sulfide excess, the effects of further altering SERT can become harder to predict. This is particularly important in people whose symptoms began after antidepressant exposure or changed significantly during or after SSRI use. The main point is not ideological. It is mechanistic. If the transporter that normally terminates serotonin signaling is already part of the problem, then long-term pharmacologic inhibition of that same transporter may interact with the system in complicated ways.

A more complete model of gut dysfunction emerges when all of these layers are integrated. Serotonin is produced and released by enterochromaffin cells. SERT controls how long serotonin remains active. Receptors such as 5-HT4 and 5-HT3 determine whether the outcome is coordinated movement or sensory overload. The MMC depends on good timing and coordinated neuronal activity to clear the small intestine during fasting. Hydrogen sulfide can disrupt transporter function and also inhibit mitochondrial respiration. Chronic receptor exposure can lead to desensitization. Reduced motility and impaired MMC function can promote bacterial persistence in the small intestine, which may further worsen the microbial environment. This can create a feedback loop rather than a one-time insult.

So the proper mechanistic question is not simply whether serotonin is high or low. The better question is whether the gut still has control over serotonin signaling, whether the receptors are still responsive, whether the tissue has the energy to move, and whether the microbial environment is pushing the system toward ongoing disruption. Once you ask those questions, the clinical picture becomes much more coherent.

This is also why the current model deserves to be challenged. The dominant way of thinking often treats motility as a single-pathway problem. If the gut is slow, stimulate it. If it is sensitive, block the signal. If it is overactive, suppress the pathway. That approach can sometimes help symptomatically, but it often misses the architecture of the problem. The gut is a coordinated system, not a single switch. If a microbial metabolite such as hydrogen sulfide is reshaping serotonin control while also impairing bioenergetics, then the target is not just serotonin. The target is the broader loss of regulation.

If this model is to be explored seriously, several points become important. It is necessary to consider the microbial side, including which organisms and substrate conditions increase hydrogen sulfide production. It is necessary to consider host detoxification capacity, because the body has mitochondrial sulfide oxidation pathways involving enzymes such as sulfide quinone oxidoreductase, ETHE1, thiosulfate sulfurtransferase, and sulfite oxidase. It is necessary to consider genetics, including variation in SLC6A4 and possibly genes influencing sulfur handling, mitochondrial resilience, and redox balance. It is also necessary to consider the role of the fasting state, meal timing, vagal tone, motilin signaling, and the integrity of enteric neural circuits. The model is strongest when serotonin is seen as one regulatory layer within a larger host-microbe-energy system.

The final lesson is simple, even if the biology is not. Gut motility becomes unstable when signaling loses timing, receptors lose responsiveness, and cells lose energy. Serotonin is central to that story, but not in the simplistic sense most people assume. The problem is not only how much serotonin exists. The problem is whether the system can still control serotonin properly. Hydrogen sulfide may matter because it can interfere with that control at multiple levels at once. Once that happens, the gut does not simply become fast or slow. It becomes disorganized. And disorganization is far harder to treat than a basic imbalance.

That is the reason this discussion matters. It shifts the question from symptom suppression to mechanism. It asks not just what drug pushes the bowel, but why the bowel lost coordination in the first place.